First aml patient successfully transplanted with vor bio's investigational trem-cel (vor33) and tolerated mylotarg™

Cambridge, mass., dec. 07, 2022 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, today announced initial clinical data from vbp101, its phase 1/2a multicenter, open-label, first-in-human study of tremtelectogene empogeditemcel or “trem-cel” (formerly vor33) in patients with acute myeloid leukemia (aml). the data observed from the first treated patient support the potential of a trem-cel transplant to be successfully manufactured, to engraft normally, and to maintain blood counts following treatment with the cd33-targeted therapy mylotarg. the clinical trial continues to enroll patients and additional data are expected in 2023.
VOR Ratings Summary
VOR Quant Ranking